Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This case report presents the first instance in Korea of unilateral gynecomastia and breast pain associated with doxazosin use.

This case report describes a 14-year-old female patient with monilethrix who developed female androgenetic alopecia at age 23, and found that oral minoxidil treatment improved her androgenetic alopecia while leaving the underlying structural hair anomalies of monilethrix unchanged.

This review found that oral minoxidil, particularly in low doses, is effective and safe for treating various types of hair loss, including androgenic alopecia, and may offer advantages over other treatments, such as improved convenience and enhancement of male sexual function.

This study found that topical 5% minoxidil solution is effective and well tolerated for promoting hair growth in Korean men with androgenetic alopecia over 24 weeks.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

In AGA animal models, this study found that finasteride-loaded microspheres provided rapid and sustained dihydrotestosterone suppression, promoting hair regrowth through dual-phase drug release.

This study found that increasing the proportion of ethanol in minoxidil formulations improved skin penetration in both in vitro and in vivo tests on mice.

This review discusses testosterone replacement therapy, highlighting that most studies report no increased myocardial infarction risk when the therapy is properly administered with controlled hormone levels; it calls for careful consideration despite insurance coverage challenges.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This study developed a micellar electrokinetic capillary chromatography method for determining minoxidil in Rogaine and generic products, offering a simple and efficient alternative to HPLC.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This study found that six months of combined estrogen-progestin pill therapy led to a significant reduction in serum AMH levels and improvement in hyperandrogenic symptoms among women with PCOS.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

This study reviewed contemporary literature and found that combining minoxidil with topical finasteride, biologic adjuvants, or delivery innovations might enhance treatment effectiveness for androgenetic alopecia compared to minoxidil alone, although diverse outcomes and incomplete data limit broader conclusions.

This study found that men with early-onset androgenic alopecia may be partially resistant to the cardiometabolic benefits of bromocriptine compared to those with normal hair growth.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

This review discusses male androgenetic alopecia treatments, noting that topical minoxidil and oral finasteride are FDA-approved and require continuous use to maintain hair retention effects, but reports no new clinical results.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This study found that minoxidil sulfate stimulates Cl channels, potentially depolarization-activated and outwardly rectifying, in eccrine clear cells, while minoxidil itself stimulates Ca-insensitive K currents.

This study found that various steroids affected the mRNA expression of enzymes involved in lipid metabolism in hamster flank organs, with different impacts depending on the steroid and combination used.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This preliminary study found that Melandrium firmum extract may promote hair growth and inhibit 5α-reductase, suggesting potential as a candidate for treating androgenetic alopecia.

This study found that minoxidil stimulates the Kir6.2/SUR2 potassium channel, leading to tumor growth arrest in an ovarian cancer xenograft model by disrupting mitochondrial function and inducing cell death.

This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.

Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.